Latest Commercial Expansion News

Control Bionics Limited has announced a $2.06 million non-renounceable rights issue to fund the commercial expansion of its NeuroStrip device and bolster NeuroNode operations. The capital raise is underwritten to approximately $1.15 million by major shareholders and strategic partners.

Micro-X reported FY25 revenue of $13.1 million, underpinned by significant US government contracts and pioneering 3D head CT imaging technology, setting the stage for clinical trials and commercial expansion.

Decidr AI Industries has locked in a $3.9 million underwriting agreement with Morgans Corporate Limited to back the exercise of listed options expiring this month, providing crucial funding ahead of its DecidrOS Beta release.

Imricor Medical Systems reports significant regulatory approvals and clinical trial progress, positioning itself as a disruptive force in the growing electrophysiology market. With a strengthened commercial pipeline and solid cash reserves, the company is poised for a pivotal growth phase.

INOVIQ Limited reported a $6.9 million net loss for FY25 while making significant strides in its exosome-based cancer diagnostics and therapeutics pipeline, including a breakthrough ovarian cancer screening test and promising CAR-exosome therapy results.

Artrya Limited reported a 17.2% increase in net loss to $16.4 million for FY25, while achieving FDA clearance and launching its AI-driven Salix platform in the U.S. market. The company also secured key commercial partnerships in Australia and raised $20 million in equity funding.

EcoGraf Limited reveals a major breakthrough in its HFfree® graphite purification technology, cutting operating costs by 25% and projecting a US$282 million NPV for its initial 25,000 tonnes per annum facility. This positions the company as a competitive, eco-friendly supplier amid rising global demand and geopolitical shifts in battery materials.

Firebird Metals has received a significant Expression of Interest from Taza Metal Technologies to purchase up to five of its energy-efficient kilns, potentially generating over US$10 million in revenue. This marks a key step in Firebird’s international commercial expansion and highlights its leadership in sustainable manganese processing technology.

Telix Pharmaceuticals has recast its historical financials from AUD to USD to better reflect its US-centric revenue streams and reports increased operating expenditure tied to recent acquisitions and growth initiatives.

Advanced Health Intelligence Ltd has secured up to AUD 5.5 million from Oakley Capital Partners to support its ASX reinstatement and global growth ambitions, while targeting an additional USD 6 million from strategic investors and unlocking AUD 3 million in R&D grants.

4DMedical has landed a $10 million strategic investment from Pro Medicus, aimed at accelerating its commercial growth and advancing its CT – VQ™ technology towards FDA clearance in the US.

4DMedical reports a 56% revenue surge in FY25 alongside a strategic $10 million investment from Pro Medicus, advancing its CT, VQ™ lung imaging technology towards FDA clearance.